Literature DB >> 6954069

Deferoxamine mesylate enhancement of 67Ga tumor-to-blood ratios and tumor imaging.

K Koizumi, N Tonami, K Hisada.   

Abstract

To improve the tumor-to-blood ratio in 67Ga tumor imaging, the effect of administration of deferoxamine mesylate (DFO) was evaluated. DFO improved 67Ga tumor-to-blood ratios in tumor-bearing rats. Administration of DFO 12 h after 67Ga injection did not decrease the concentration of radioactivity in the tumor of rats, but administration of DFO 4 h after 67Ga decreased the concentration of radioactivity in the tumor. Serum unsaturated iron binding capacity in rats was transiently increased by DFO administration, but when DFO was administered before 67Ga injection the tumor uptake showed rather decreased levels. In human studies, DFO accelerated the excretion of 67Ga from the blood, but tumor images were not necessarily improved.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6954069     DOI: 10.1007/bf00256470

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  7 in total

Review 1.  Mechanisms of localization of gallium-67 in tumors.

Authors:  S M Larson
Journal:  Semin Nucl Med       Date:  1978-07       Impact factor: 4.446

2.  Effects of desferrioxamine on 67Ga distributions in tumor-bearing mice.

Authors:  R G Sephton; S De Abrew
Journal:  Proc Soc Exp Biol Med       Date:  1979-07

Review 3.  Gallium: mechanisms.

Authors:  P Hoffer
Journal:  J Nucl Med       Date:  1980-03       Impact factor: 10.057

4.  The effects of deferoxamine mesylate on gallium-67 distribution in normal and abscess-bearing animals: concise communication.

Authors:  Z H Oster; P Som; D F Sacker; H L Atkins
Journal:  J Nucl Med       Date:  1980-05       Impact factor: 10.057

5.  Desferoxamine mesylate (Desferal): a contrast-enhancing agent for gallium-37 imaging.

Authors:  P B Hoffer; A Samuel; J T Bushberg; M Thakur
Journal:  Radiology       Date:  1979-06       Impact factor: 11.105

6.  Pharmacologic enhancement of gallium-67 tumor-to-blood ratios for EMT-6 sarcoma (BALB/c mice).

Authors:  S M Larson; J S Rasey; Z Grunbaum; D R Allen
Journal:  Radiology       Date:  1979-01       Impact factor: 11.105

7.  Effect of desferoxamine on tissue and tumor retention of gallium-67: concise communication.

Authors:  P B Hoffer; A Samuel; J T Bushberg; M Thakur
Journal:  J Nucl Med       Date:  1979-03       Impact factor: 10.057

  7 in total
  4 in total

1.  Gallium-67 scintigraphy in patients with hemochromatosis treated by deferoxamine.

Authors:  S Nagamachi; H Hoshi; S Jinnouchi; S Ono; K Watanabe
Journal:  Ann Nucl Med       Date:  1988-05       Impact factor: 2.668

2.  Preparation of 67Ga-labelled human IgG and its Fab fragments using desferoxamine as chelating agent.

Authors:  C Motta-Hennessy; S A Eccles; C Dean; G Coghlan
Journal:  Eur J Nucl Med       Date:  1985

Review 3.  Siderophores for molecular imaging applications.

Authors:  Milos Petrik; Chuangyan Zhai; Hubertus Haas; Clemens Decristoforo
Journal:  Clin Transl Imaging       Date:  2016-10-11

4.  Manipulating the In Vivo Behaviour of 68Ga with Tris(Hydroxypyridinone) Chelators: Pretargeting and Blood Clearance.

Authors:  Cinzia Imberti; Pierre Adumeau; Julia E Blower; Fahad Al Salemee; Julia Baguña Torres; Jason S Lewis; Brian M Zeglis; Samantha Y A Terry; Philip J Blower
Journal:  Int J Mol Sci       Date:  2020-02-22       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.